2QB0 Stock Chart & Stats
€0.24
-€0.01(-5.60%)
At close: 4:00 PM EDT
€0.24
-€0.01(-5.60%)
Day’s Range― - ―
52-Week Range€0.20 - €0.71
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€37.11M
Enterprise Value€63.76M
Total Cash (Recent Filing)€88.74K
Total Debt (Recent Filing)€4.31M
Price to Earnings (P/E)―
Beta-0.42
Next Earnings
Dec 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding143,983,700
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.19
Price to Book (P/B)-18.65
Price to Sales (P/S)0.00
P/FCF Ratio-21.06
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Defined Ophthalmic Product FocusA clearly defined ophthalmic implant gives the company a focused product strategy rather than a broad, unfocused development agenda. If successfully validated and commercialized, the technology could address vision correction through a differentiated medical-device offering.
Commercialization PreparationThe company is progressing beyond basic concept development by combining research with clinical, regulatory, and commercialization preparation. This coordinated pathway can support eventual market entry and provides a structured foundation for advancing the Bionic Lens.
Debt Reduced From 2025Lower total debt compared with 2025 is a modest balance-sheet improvement that could reduce financial pressure relative to the prior period. The benefit is limited by negative equity and high leverage, but the direction of debt movement is nevertheless supportive.
Bears Say
No Meaningful Commercialization YetPersistent zero revenue indicates that the company has not yet established commercial demand or a functioning revenue stream. Until the product reaches market and generates sales, operations remain dependent on financing and development progress rather than internally funded growth.
Widening Operating LossesLosses are increasing materially while revenue remains absent, showing that the company is moving farther from profitability rather than demonstrating operating leverage. Continued widening losses can consume capital, limit strategic flexibility, and raise the funding required to reach commercialization.
Weak Capitalization And Cash BurnNegative equity, debt exceeding the asset base, and substantial operating cash outflows create a fragile financial structure. The company may need repeated external funding to sustain development, increasing dilution risk and reducing its ability to absorb setbacks.
Ocumetics Technology Corp News
2QB0 FAQ
What was Ocumetics Technology Corp’s price range in the past 12 months?
Ocumetics Technology Corp lowest stock price was €0.20 and its highest was €0.71 in the past 12 months.
What is Ocumetics Technology Corp’s market cap?
Ocumetics Technology Corp’s market cap is €37.11M.
When is Ocumetics Technology Corp’s upcoming earnings report date?
Ocumetics Technology Corp’s upcoming earnings report date is Dec 01, 2026 which is in 35 days.
How were Ocumetics Technology Corp’s earnings last quarter?
Ocumetics Technology Corp released its earnings results on Aug 28, 2026. The company reported -€0.002 earnings per share for the quarter.
Is Ocumetics Technology Corp overvalued?
According to Wall Street analysts Ocumetics Technology Corp’s price is currently Overvalued.
Does Ocumetics Technology Corp pay dividends?
Ocumetics Technology Corp does not currently pay dividends.
What is Ocumetics Technology Corp’s EPS estimate?
Ocumetics Technology Corp’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ocumetics Technology Corp have?
Ocumetics Technology Corp has 143,983,700 shares outstanding.
What happened to Ocumetics Technology Corp’s price movement after its last earnings report?
Ocumetics Technology Corp reported an EPS of -€0.002 in its last earnings report. Following the earnings report the stock price went down -1.77%.
Which hedge fund is a major shareholder of Ocumetics Technology Corp?
Currently, no hedge funds are holding shares in DE:2QB0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ocumetics Technology Corp
Ocumetics Technology Corp. is an innovation-driven enterprise specializing in the development and production of diverse optical lenses. One of its key innovations is the Bionic Lens, an expandable intraocular lens crafted to be implanted within the eye's natural lens compartment, offering a solution that eliminates the need for external vision correction. The company maintains its corporate headquarters in Calgary, Canada.
Technical Analysis
Aurora Spine
―
Covalon Technologies
―
Perimeter Medical Imaging AI
―
VentriPoint Diagnostics
―
Conavi Medical
―